ESTRO 2024 - Abstract Book

S716

Clinical - Breast

ESTRO 2024

• Ipsilateral Lung V8Gy: Median Value: 17.9 cc (IQR: 13.89 – 21.27) • PTV_D90: Median Value: 24.08 Gy (IQR: 23.67 – 24.47)

Conclusion:

The use of ultrahypofractionated breast radiation therapy is feasible and effective. Toxicities reported in this study were mild while acceptable OS of 95.6% was achieved.

Keywords: Ultrahypofractionated, Breast, Survival

References:

[1] Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613-1626. doi:10.1016/S0140-6736(20)30932-6

3111

Digital Poster

An exercise regimen to improve mobility, body composition and strength after breast cancer treatment

Colin E. Champ 1,2 , Chris Peluso 2 , Christie Hilton 3 , Sushil Beriwal 1 , David J Carpenter 4

1 Allegheny Health Network, Radiation Oncology, Pittsburgh, USA. 2 Allegheny Health Network, Exercise Oncology & Resiliency Center, Pittsburgh, USA. 3 Allegheny Health Network, Medical Oncology, Pittsburgh, USA. 4 Wellstar Paulding Medical Center, Radiation Oncology, Hiram, USA

Purpose/Objective:

Resistance training may offer several unique advantages within breast cancer (BC) survivorship care; however, safety concerns have limited the application of high-intensity compound movements necessary to elicit optimal changes in body composition, strength, and quality of life in this population. The EXERT-BC trial assesses the safety and feasibility of an evidence-based, dose-escalated resistance training regimen among BC survivors, with the goal of improving physical and metabolic function, mobility, muscle mass, and body composition. This trial is registered with clinicaltrials.gov, trial number NCT05747209.

Material/Methods: